Changes in olfactory function observed with DUPIXENT® and

placebo

DUPIXENT® significantly improved UPSIT score from baseline vs. placebo + INCS at week 24 and week 521,3

Line graph showing the LS mean change from baseline in UPSIT score in SINUS-52, which was a secondary endpoint. The x-axis ranges from Weeks 0 through 52. 150 patients were in the DUPIXENT treatment arm and 153 patients were in the placebo arm. At Week 52, a 9.53-point improvement was seen in the DUPIXENT arm (from a baseline UPSIT score of 13.46) compared with a 0.77-point worsening in the placebo arm (from a baseline score of 13.78). The LS mean different was 10.30 with a 95% confidence interval of 8.50 to 12.10.

University of Pennsylvania Smell Identification Test (UPSIT) assesses olfactory function with a 40-odorant test. The score ranges from 0 to 40 (35-40=normal smell appreciation; 31-34=mild microsmia; 26-30=moderate microsmia; 19-25=severe microsmia; <18=anosmia). Higher score indicates improvement.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo